Jacobio Pharmaceuticals Group Co. Ltd. announced its unaudited condensed consolidated interim results for the six months ended June 30, 2025. The company reported a significant increase in revenue from RMB0 in the first half of 2024 to RMB45.7 million in the same period in 2025, driven by milestone payments from the Allist Licensing Agreement. The cost of revenue remained at zero, resulting in a gross profit of RMB45.7 million, up from nil in the previous year. Despite increased revenue, the company recorded a net loss of RMB59.0 million for the reporting period, a notable improvement from the RMB169.1 million loss in the first half of 2024. This reduction in loss was attributed to stringent controls on discretionary incidental expenditures and enhanced operational efficiency across administrative functions. Jacobio Pharmaceuticals continues to focus on significant advancements in cancer biology, particularly in areas such as KRAS, MYC, p53, and immune-oncology, including immune checkpoints like PD-1 and PD-$(L)$1.